Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis
Abstract
A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMκ-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20 + cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of amyloidogenic immunoglobulin light chains.